Published in Vaccine Weekly, June 26th, 2002
The collaboration will pool Berna's expertise in the development of vaccines and novel adjuvants with Iomai's expertise in skin delivery using its proprietary patch technology. Needle-free delivery has become a global priority because of the risk of needle-borne diseases associated with reuse and improper disposal of needles. Delivery of vaccines across the skin using a patch not only addresses this issue, but may elicit a stronger immune response through delivery to the skin, an area rich in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly